A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation
A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation
复制标题
DOI：
10.1038/s41467-020-17892-0
复制
发表时间：
2020-08-13
影响因子：
16.6
通讯作者：
Shi, Pei-Yong
中科院分区：
文献类型：
--
作者：
Muruato, Antonio E.;Fontes-Garfias, Camila R.;Shi, Pei-Yong
病毒中和仍然是确定抗体效力的金标准。因此，新冠肺炎的血清诊断、恢复期血浆治疗和疫苗开发迫切需要一种高通量检测SARS-CoV-2中和抗体的方法。在这里，我们报告了一种基于荧光的SARS-CoV-2中和试验，该方法检测新冠肺炎患者标本中的SARS-CoV-2中和抗体，并产生与血清学检测的金标准--空斑减少中和试验类似的结果。这种基于荧光的中和试验专门用于检测新冠肺炎中和抗体，而不会与其他病毒、细菌或寄生虫感染的患者标本发生交叉反应。总的来说，我们的方法提供了一个快速平台，可以扩展到对人们进行新冠肺炎抗体保护筛查，这是安全重新开放当地社区所必需的关键参数。
Virus neutralization remains the gold standard for determining antibody efficacy. Therefore, a high-throughput assay to measure SARS-CoV-2 neutralizing antibodies is urgently needed for COVID-19 serodiagnosis, convalescent plasma therapy, and vaccine development. Here, we report on a fluorescence-based SARS-CoV-2 neutralization assay that detects SARS-CoV-2 neutralizing antibodies in COVID-19 patient specimens and yields comparable results to plaque reduction neutralizing assay, the gold standard of serological testing. The fluorescence-based neutralization assay is specific to measure COVID-19 neutralizing antibodies without cross reacting with patient specimens with other viral, bacterial, or parasitic infections. Collectively, our approach offers a rapid platform that can be scaled to screen people for antibody protection from COVID-19, a key parameter necessary to safely reopen local communities.